Valuation: Cogent Biosciences, Inc.

Market Cap 6.8B 5.97B 5.55B 5.09B 9.57B 654B 9.72B 65.91B 25.75B 322B 25.51B 24.96B 1,112B P/E 2026 *
-17.4x
P/E 2027 * -48.7x
Enterprise Value 6.74B 5.92B 5.51B 5.05B 9.49B 649B 9.64B 65.38B 25.54B 319B 25.3B 24.76B 1,103B EV / Sales 2026 *
681x
EV / Sales 2027 * 19.3x
Free-Float
99.5%
Yield 2026 *
-
Yield 2027 * -
1 day-1.19%
1 week+1.74%
Current month+2.74%
1 month+5.94%
3 months+8.01%
6 months+8.40%
Current year+11.94%
1 week 38.04
Extreme 38.04
40.55
1 month 37
Extreme 37
40.89
Current year 30.87
Extreme 30.87
41.35
1 year 10.38
Extreme 10.38
43.73
3 years 3.67
Extreme 3.67
43.73
5 years 3.67
Extreme 3.67
43.73
10 years 3.67
Extreme 3.67
43.73
Manager TitleAgeSince
Chief Executive Officer 50 23/10/2020
Director of Finance/CFO 45 01/06/2018
Chief Tech/Sci/R&D Officer 52 06/04/2021
Director TitleAgeSince
Director/Board Member 68 01/02/2018
Director/Board Member 74 26/07/2019
Director/Board Member 59 26/07/2019
Date Insider Type Main position Quantity % Market Cap.
01/07/26 Free

Director

627 0.0004%
09/06/26 Free

Director

17,901 0.0105%
09/06/26 Free

Director

17,901 0.0105%
Change 5-day change 1-year change 3-year change Capi.($)
-1.19%+1.74%+226.17%+217.57% 6.8B
+0.93%+6.97%+62.83%+67.97% 57.28B
-1.92%+6.03%+43.68%+84.56% 54.99B
-0.46%-1.29%+3.28%+422.58% 23.18B
-2.97%-2.35%-22.03%-16.54% 22.59B
-0.36%+5.73%+30.99%-3.58% 20.46B
-1.34%+0.51%+25.02%-30.27% 17.56B
-1.44%+5.67%+32.54%+544.11% 15.67B
-1.30%-5.02%+165.62%+291.37% 14.46B
-0.50%-0.98%+23.62%+178.38% 13.92B
Average -1.06%+1.32%+59.17%+175.62% 24.69B
Weighted average by Cap. -0.88%+2.09%+46.27%+137.94%

Financials

2026 *2027 *
Net sales 9.9M 8.7M 8.09M 7.42M 13.95M 954M 14.16M 96.05M 37.53M 469M 37.18M 36.37M 1.62B 349M 306M 285M 262M 491M 33.6B 499M 3.38B 1.32B 16.52B 1.31B 1.28B 57.11B
Net income -392M -344M -320M -293M -551M -37.71B -560M -3.8B -1.48B -18.54B -1.47B -1.44B -64.1B -132M -116M -108M -98.7M -185M -12.68B -188M -1.28B -499M -6.23B -494M -484M -21.56B
Net Debt -55.22M -48.5M -45.1M -41.39M -77.76M -5.32B -78.96M -536M -209M -2.61B -207M -203M -9.04B -63.88M -56.1M -52.17M -47.88M -89.96M -6.15B -91.34M -620M -242M -3.02B -240M -235M -10.46B
Logo Cogent Biosciences, Inc.
Cogent Biosciences, Inc. is a clinical-stage biotechnology company. It is focused on developing precision therapies for genetically defined diseases. Its approach is to design rational precision therapies that treat the underlying cause of disease and improve the lives of patients. Its advanced program is bezuclastinib, also known as CGT9486, a highly selective tyrosine kinase inhibitor that is designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. KIT D816V is responsible for driving systemic mastocytosis (SM), a serious and rare disease caused by unchecked proliferation of mast cells. The Company has on-going Phase I studies of its CNS-penetrant, selective mutant ErbB2 inhibitor and its potential best-in-class, wild-type-sparing, PI3Ka inhibitor. In addition, the Company’s research team is developing a portfolio of novel targeted therapies to help patients fighting serious, genetically driven diseases targeting mutations in KRAS and JAK2.
Employees
258
Date Price Change Volume
24/07/26 $39.76 -1.19% 1,593,419
23/07/26 $40.24 +1.77% 3,181,309
22/07/26 $39.54 -0.25% 1,941,814
21/07/26 $39.64 +3.50% 1,294,540
20/07/26 $38.30 -2.00% 1,170,458
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
13
Last Close Price
39.76USD
Average target price
54.25USD
Spread / Average Target
+36.44%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. COGT Stock